Diaprost AB
Share:
Subscribe:

Johan Drott vd CEO Diaprost AB Jan 2020

Tue, Jan 21, 2020 10:50 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer. Tue, Sep 28, 2021 09:00 CET

Diaprost Announces Promising New Study for Patients with Metastatic PCa Mon, Feb 22, 2021 08:00 CET

Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center Tue, Aug 25, 2020 08:00 CET